What is the recommended management of acute shingles pain and prevention of post‑herpetic neuralgia?

Management of Acute Shingles Pain and Prevention of Post-Herpetic Neuralgia

For acute shingles pain, initiate antiviral therapy within 72 hours of rash onset and start gabapentin or pregabalin immediately for pain control; for established post-herpetic neuralgia, use gabapentin, pregabalin, or topical capsaicin 8% as first-line therapy, with tricyclic antidepressants as second-line options.

Acute Phase Management (First 72 Hours)

Antiviral Therapy

• Start antiviral medication immediately upon diagnosis, ideally within 72 hours of rash appearance to reduce acute pain duration and decrease PHN incidence 1, 2, 3
• Options include acyclovir, valacyclovir, or famciclovir 2
• Rapid initiation directly correlates with better outcomes for both acute pain resolution and PHN prevention 3

Acute Pain Control

• Begin gabapentin or pregabalin at the onset of acute shingles rather than waiting for PHN to develop 4
• Start with low doses in older adults: pregabalin 25-50 mg/day or gabapentin 100-200 mg/day, titrating slowly 4
• Target doses: pregabalin 150-600 mg/day in two divided doses; gabapentin 900-3600 mg/day in 2-3 divided doses 4
• Somnolence, dizziness, and mental clouding are common, particularly problematic in elderly patients 4

What NOT to Do in Acute Phase

• Do not prescribe tricyclic antidepressants or corticosteroids during acute HZ 3
• These are ineffective for acute pain and corticosteroids carry significant risks without proven benefit in this phase 3

Post-Herpetic Neuralgia Management (Pain >90 Days)

First-Line Pharmacological Options

Gabapentinoids (Preferred Initial Choice)

• Gabapentin is recommended as first-line oral treatment, titrating to 2400 mg/day in divided doses 4
• Pregabalin may be considered for PHN patients, with easier titration due to favorable pharmacokinetics 4
• Both improve sleep scores in addition to pain relief 4

Topical Capsaicin (Strong Evidence)

• 8% capsaicin dermal patch provides the strongest evidence (strong recommendation, high-quality evidence) 4
• Single 30-minute application provides pain relief for at least 12 weeks 4
• Pre-treat with 4% lidocaine for 60 minutes before capsaicin application to minimize burning and erythema, then wipe off lidocaine 4
• Particularly useful for localized peripheral neuropathic pain 4, 5

Topical Lidocaine

• 5% lidocaine patches are first-line for localized PHN 4, 5, 6
• Can be used alone or combined with systemic agents 4
• High safety profile due to minimal systemic absorption, especially important in older adults 4

Second-Line Options (If Inadequate Response to Gabapentin)

Serotonin-Norepinephrine Reuptake Inhibitors

• Consider duloxetine or venlafaxine based on effectiveness in general neuropathic pain populations 4
• Weak recommendation, moderate evidence 4

Tricyclic Antidepressants

• Nortriptyline or desipramine (secondary amines preferred over tertiary amines) 4, 5, 6
• Start with low bedtime doses and titrate slowly 4
• Obtain screening ECG for patients >40 years; use caution with cardiac disease 4
• Limit doses to <100 mg/day when possible; allow 6-8 weeks for adequate trial 4
• Anticholinergic effects (dry mouth, orthostatic hypotension, constipation, urinary retention) limit tolerability 4

Combination Therapy Strategy

• If partial relief with first-line monotherapy (pain remains ≥4/10), add a second first-line agent rather than switching 4
• Topical agents can be combined with systemic medications for optimal outcomes 4, 6
• If <30% pain reduction after adequate trial at target dose, switch to alternative first-line medication 4

Non-Pharmacological Approaches

Cognitive Behavioral Therapy

• Recommended for chronic neuropathic pain management (strong recommendation, moderate evidence) 4
• Promotes adaptive behaviors while addressing pain-related avoidance 4

Other Modalities

• Hypnosis is recommended specifically for neuropathic pain (strong recommendation, low evidence) 4
• Physical and occupational therapy are recommended (strong recommendation, low evidence) 4

Critical Pitfalls to Avoid

Timing Errors

• Delaying antiviral therapy beyond 72 hours significantly reduces effectiveness 2, 3
• Waiting for PHN to develop before starting neuropathic pain medications—start gabapentinoids during acute phase 4

Medication Selection Errors

• Using tricyclic antidepressants in acute phase (ineffective and potentially harmful) 3
• Prescribing corticosteroids for acute HZ pain (no proven benefit, significant risks) 3
• Starting with high doses of gabapentinoids in elderly patients (increases adverse effects and discontinuation) 4

Monitoring Failures

• Not obtaining baseline ECG before TCA use in patients >40 years 4
• Inadequate trial duration—TCAs require 6-8 weeks including 2 weeks at maximum tolerated dose 4
• Failing to adjust doses for renal impairment with gabapentinoids 4

Treatment Algorithm Summary

1. Acute phase (<72 hours): Antiviral + gabapentin/pregabalin (low starting dose)
2. If pain persists at 90 days (PHN): Continue or optimize gabapentinoid dose; add topical capsaicin 8% or lidocaine 5%
3. If inadequate response: Add SNRI or TCA as second agent
4. If still inadequate: Switch to alternative first-line agent or refer to pain specialist 4
5. Target outcome: Pain ≤3/10 with tolerable side effects 4